Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Lacunar stroke

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44335   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    25 result(s) found for: Lacunar stroke. Displaying page 1 of 2.
    1  2  Next»
    EudraCT Number: 2016-000896-26 Sponsor Protocol Number: ETLAS Start Date*: 2016-05-19
    Sponsor Name:Herlev Gentofte Hospital
    Full Title: Effect of Tadalafil on cerebral large arteries in stroke patients.
    Medical condition: Stroke and small vessel disease.
    Disease: Version SOC Term Classification Code Term Level
    19.0 10029205 - Nervous system disorders 10070879 Cerebral small vessel ischemic disease LLT
    19.0 10029205 - Nervous system disorders 10076994 Lacunar stroke PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2020-002329-27 Sponsor Protocol Number: ETLAS-2 Start Date*: 2020-12-10
    Sponsor Name:Herlev Gentofte Hospital
    Full Title: Improving cerebral blood flow and cognition in patient with cerebral small vessel disease. The ETLAS-2 Trial.
    Medical condition: Cerebral small vessel disease and stroke.
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029205 - Nervous system disorders 10070879 Cerebral small vessel ischemic disease LLT
    22.1 10029205 - Nervous system disorders 10076994 Lacunar stroke PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2016-002277-35 Sponsor Protocol Number: AC16093 Start Date*: 2017-06-01
    Sponsor Name:University of Edinburgh [...]
    1. University of Edinburgh
    2. NHS Lothian
    Full Title: LACunar Intervention (LACI-2) Trial-2: Assessment of safety and efficacy of cilostazol and isosorbide mononitrate to prevent recurrent lacunar stroke and progression of cerebral small vessel disease.
    Medical condition: lacunar (small vessel) ischaemic stroke
    Disease: Version SOC Term Classification Code Term Level
    20.1 10029205 - Nervous system disorders 10071043 Basal ganglia stroke PT
    20.0 10029205 - Nervous system disorders 10068644 Brain stem stroke PT
    20.0 10029205 - Nervous system disorders 10023987 Late effects of cerebrovascular disease LLT
    20.0 10029205 - Nervous system disorders 10061256 Ischaemic stroke PT
    20.0 10029205 - Nervous system disorders 10042244 Stroke LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: View results
    EudraCT Number: 2015-001235-20 Sponsor Protocol Number: 14.0189 Start Date*: 2015-06-05
    Sponsor Name:St George's University of London
    Full Title: Perfusion by Arterial Spin labelling following Single dose Tadalafil In Small vessel disease
    Medical condition: PARTICIPANTS WITH EVIDENCE OF CEREBRAL SMALL VESSEL DISEASE
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2022-001067-27 Sponsor Protocol Number: 20604 Start Date*: 2022-11-10
    Sponsor Name:Bayer AG
    Full Title: A multicenter, international, randomized, placebo controlled, double-blind, parallel group and event driven Phase 3 study of the oral FXIa inhibitor asundexian (BAY 2433334) for the prevention of i...
    Medical condition: Prevention of ischemic stroke in patients post acute non-cardioembolic ischemic stroke or high-risk transient ischemic attack
    Disease: Version SOC Term Classification Code Term Level
    20.0 10042613 - Surgical and medical procedures 10049165 Cerebrovascular accident prophylaxis PT
    22.1 100000004852 10055221 Ischemic stroke LLT
    20.1 100000004852 10072760 Transient ischemic attack LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Trial now transitioned) FI (Trial now transitioned) SE (Trial now transitioned) NO (Trial now transitioned) LT (Trial now transitioned) HU (Trial now transitioned) ES (Trial now transitioned) AT (Trial now transitioned) FR (Trial now transitioned) IT (Trial now transitioned) BE (Trial now transitioned) GR (Trial now transitioned) CZ (Trial now transitioned) NL (Trial now transitioned) PL (Trial now transitioned) LV (Trial now transitioned) PT (Trial now transitioned) BG (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2013-003444-24 Sponsor Protocol Number: 1160.189 Start Date*: 2014-11-21
    Sponsor Name:Unilfarma - União Internacional de Lab. Farmacêuticos, Lda.
    Full Title: Randomized, double-blind, Evaluation in secondary Stroke Prevention comparing the EfficaCy and safety of the oral Thrombin inhibitor dabigatran etexilate (110 mg or 150 mg, oral b.i.d.) versus acet...
    Medical condition: A study to compare dabigatran etexilate to acetylsalicylic acid in preventing recurrent stroke for patients that already had a stroke caused by an embolus (clot). Despite testing, it is unknown wh...
    Disease: Version SOC Term Classification Code Term Level
    18.1 10029205 - Nervous system disorders 10067167 Cerebellar embolism PT
    18.1 10029205 - Nervous system disorders 10014498 Embolic stroke PT
    18.1 10029205 - Nervous system disorders 10060839 Embolic cerebral infarction PT
    18.1 10029205 - Nervous system disorders 10074422 Brain stem embolism PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PT (Completed) DE (Completed) BE (Completed) AT (Completed) HU (Completed) IT (Completed) SE (Completed) SI (Completed) ES (Completed) CZ (Completed) SK (Completed) PL (Completed) HR (Completed) GR (Completed) EE (Completed)
    Trial results: View results
    EudraCT Number: 2013-000768-27 Sponsor Protocol Number: BAY59-7939/16573 Start Date*: 2015-01-29
    Sponsor Name:Bayer HealthCare AG
    Full Title: Multicenter, randomized, double-blind, double-dummy, active-comparator, event-driven, superiority phase III study of secondary prevention of stroke and prevention of systemic embolism in patients w...
    Medical condition: Embolic stroke of undetermined source (ESUS)
    Disease: Version SOC Term Classification Code Term Level
    17.0 10029205 - Nervous system disorders 10014498 Embolic stroke PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) IE (Prematurely Ended) PT (Prematurely Ended) CZ (Completed) BE (Completed) ES (Completed) IT (Prematurely Ended) HU (Completed) FI (Prematurely Ended) DK (Prematurely Ended) GB (Prematurely Ended) AT (Prematurely Ended) GR (Completed)
    Trial results: View results
    EudraCT Number: 2015-001953-33 Sponsor Protocol Number: PrevSVD-2015 Start Date*: 2015-10-09
    Sponsor Name:University of Edinburgh [...]
    1. University of Edinburgh
    2. NHS Lothian
    Full Title: Preventing cognitive decline and dementia from cerebral small vessel disease
    Medical condition: Lacunar (small vessel) ischaemic stroke
    Disease: Version SOC Term Classification Code Term Level
    19.0 10029205 - Nervous system disorders 10023987 Late effects of cerebrovascular disease LLT
    19.0 10029205 - Nervous system disorders 10042244 Stroke LLT
    19.0 10029205 - Nervous system disorders 10061256 Ischaemic stroke PT
    19.0 10029205 - Nervous system disorders 10068644 Brain stem stroke PT
    19.0 10029205 - Nervous system disorders 10071043 Basal ganglia stroke PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2006-005345-11 Sponsor Protocol Number: RA2364 Start Date*: 2007-08-08
    Sponsor Name:University of Nottingham
    Full Title: ‘Stem cell Trial of recovery EnhanceMent after Stroke 2’ (STEMS2) pilot randomised placebo-controlled trial of granulocyte-colony stimulating factor in mobilising bone marrow stem cells in sub-acu...
    Medical condition: Ischaemic and Haemorrhagic Stroke
    Disease: Version SOC Term Classification Code Term Level
    8.1 10042244 Stroke LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2014-005109-19 Sponsor Protocol Number: ATTICUS Start Date*: 2015-11-10
    Sponsor Name:University Hospital Tuebingen
    Full Title: Apixaban for treatment of embolic stroke of undetermined source
    Medical condition: Patients with embolic stroke of undetermined source and at least on risk factor for cardiac embolism
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2008-007031-41 Sponsor Protocol Number: BIAS1.0 Start Date*: 2009-09-17
    Sponsor Name:Center for Stroke Research Berlin - Charité Universitätsmedizin Berlin
    Full Title: Beta-Blocker in Acute Ischemic Stroke – a prospective, randomized, double-blinded, placebo-controlled safety and efficacy trial of early treatment
    Medical condition: Acute ischemic stroke in the A. cerebri media territory
    Disease: Version SOC Term Classification Code Term Level
    9.1 10055221 Ischemic stroke LLT
    9.1 10061256 Ischaemic stroke LLT
    9.1 10027580 Middle cerebral artery stroke LLT
    9.1 10061256 Ischaemic stroke PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2015-004505-16 Sponsor Protocol Number: CONVINCE Start Date*: 2016-08-08
    Sponsor Name:University College Dublin
    Full Title: CONVINCE - (COlchicine for preventioN of Vascular Inflammation in Non- CardioEmbolic stroke) – a randomised clinical trial of low-dose colchicine for secondary prevention after stroke
    Medical condition: The prevention of recurrent stroke and coronary events (fatal and non- fatal) after ischaemic stroke and transient ischaemic attack (TIA) not caused by cardiac embolism or other causes unrelated to...
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10044376 Transient cerebrovascular events HLT
    20.0 100000004866 10008205 Cerebrovascular embolism and thrombosis HLT
    22.1 10029205 - Nervous system disorders 10023027 Ischaemic stroke NOS LLT
    21.1 100000004866 10051615 Atherosclerotic cardiovascular disease LLT
    20.0 10029205 - Nervous system disorders 10007962 Central nervous system vascular disorders NEC HLT
    20.0 10029205 - Nervous system disorders 10007963 Central nervous system vascular disorders HLGT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IE (Completed) ES (Completed) GB (GB - no longer in EU/EEA) DE (Completed) CZ (Completed) DK (Completed) PT (Completed) BE (Completed) LT (Completed) NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-005029-19 Sponsor Protocol Number: CV010031 Start Date*: 2020-06-09
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: A Global, Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study of BMS-986177, an Oral Factor XIa Inhibitor, for the Prevention of New Ischemic Stroke or New Covert Brain Infarc...
    Medical condition: Ischemic Stroke or Transient Ischemic Attack (TIA)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029205 - Nervous system disorders 10044390 Transient ischaemic attack PT
    22.1 10029205 - Nervous system disorders 10061256 Ischaemic stroke PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) DE (Completed) ES (Ongoing) SE (Completed) HU (Completed) NO (Completed) FI (Completed) BE (Completed) GB (GB - no longer in EU/EEA) AT (Completed) DK (Completed) GR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2019-001724-35 Sponsor Protocol Number: AMASCIS-02 Start Date*: 2020-06-16
    Sponsor Name:Fundación para la Investigación Biomédica del Hospital Universitario de La Paz (FIBHULP)
    Full Title: AMASCIS-02. ALOGENIC ADIPOSE TISSUE-DERIVED MESENCHYMAL STEM CELLS IN ISCHEMIC STROKE. A PHASE IIB MULTICENTER DOUBLE BLIND PLACEBO CONTROLLED CLINICAL TRIAL.
    Medical condition: Moderate-severe ischemic stroke
    Disease: Version SOC Term Classification Code Term Level
    22.1 100000004852 10055221 Ischemic stroke LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2015-001824-43 Sponsor Protocol Number: DS1040-A-U103 Start Date*: 2016-02-04
    Sponsor Name:Daiichi Sankyo, Inc.
    Full Title: A Phase 1b/2, multi-center, double-blind (principal investigators and study subjects blinded, sponsor unblinded), placebo-controlled, randomized, single-ascending dose study to assess the safety, p...
    Medical condition: DS-1040b is an inhibitor of the activated form of thrombin-activatable fibrinolysis inhibitor (TAFIa) intended to be used for the treatment of thrombotic diseases including acute ischemic stroke (A...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) FR (Completed) GB (Completed) CZ (Completed) ES (Completed) SK (Completed) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2013-001989-42 Sponsor Protocol Number: TEA-Stroke Start Date*: 2013-08-02
    Sponsor Name:Boris Modrau
    Full Title: Theophylline Effect in Acute Ischemic Stroke Trial
    Medical condition: Acute ischemic stroke patients eligible for standard intravenous recombinant tissue plasminogen activator (rtPA) thrombolytic therapy with magnet resonance imaging (MRI)-proved infarction
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004852 10023027 Ischaemic stroke NOS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2020-000334-17 Sponsor Protocol Number: TRACK_001 Start Date*: 2023-03-31
    Sponsor Name:The George Institute of Global Health
    Full Title: Treatment of cardiovascular disease with low Rivaroxaban in Advanced Chronic Kidney Disease - TRACK trial
    Medical condition: Improvement of cardiovascular outcomes in patients with advanced chronic kidney disease.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2016-002920-10 Sponsor Protocol Number: TRE-1486--0105-I Start Date*: 2016-09-14
    Sponsor Name:Klinikum der Universitaet Muenchen AoeR
    Full Title: TREAT-SVDs: EffecTs of Amlodipine and other Blood PREssure Lowering Agents on Microvascular FuncTion in Small Vessel Diseases
    Medical condition: Cerebral small vessel disease
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) NL (Ongoing) GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2005-003242-34 Sponsor Protocol Number: 67103 Start Date*: 2005-11-21
    Sponsor Name:National Institutes of Neurological Disorders: Stroke
    Full Title: Secondary Prevention of Small Subcortical Strokes
    Medical condition: Secondary prevention of small subcortical strokes
    Disease: Version SOC Term Classification Code Term Level
    15.0 10029205 - Nervous system disorders 10063751 Ministroke LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: (No results available)
    EudraCT Number: 2015-003188-13 Sponsor Protocol Number: CONIVAD Start Date*: 2016-09-23
    Sponsor Name:AZIENDA OSPEDALIERO-UNIVERSITARIA CAREGGI
    Full Title: Pilot study on the association choline alphoscerate-nimodipine in patients with subcortical vascular cognitive impairment
    Medical condition: Subcortical vascular cognitive impairment
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004852 10009843 Cognitive deterioration LLT
    Population Age: Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat May 10 08:29:45 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA